Apomorphine may edge ropinirole in urgent canine decontamination

CURRENT BRIEF VERSION: Apomorphine still appears to outperform ropinirole when speed matters most in canine decontamination, even as ropinirole remains the only FDA-approved emetic for dogs in the U.S. A 2025 comparative study in Journal of Veterinary Emergency and Critical Care found ropinirole had a lower first-dose success rate, took longer to trigger emesis, and was associated with more minor adverse events and more prolonged vomiting requiring rescue therapy than apomorphine in emergency patients. The trial was a prospective, randomized study conducted at 2 specialty referral hospitals from October 2021 to March 2023 in 132 client-owned dogs with suspected or confirmed toxin or foreign-body ingestion; dogs were excluded if they were younger than 4.5 months, weighed less than 1.8 kg, had ocular disease, CNS or hepatic disease, had ingested a contraindicated substance such as a caustic or volatile agent, or had already received antiemetics. That adds a new real-world counterpoint to earlier studies, including a 2023 JAVMA paper and a 2025 healthy-dog trial, which suggested ropinirole can achieve high overall emetic success and similar gastric evacuation, but often with slower onset than IV apomorphine. Meanwhile, ropinirole ophthalmic solution, sold as Clevor, has been FDA-approved since June 16, 2020, and remains the first and only approved product for inducing vomiting in dogs. (fda.gov)

Why it matters: For veterinary professionals, the comparison is less about whether both drugs work and more about which tool fits the case in front of you. Apomorphine remains familiar, fast, and, in some datasets, clinically superior for urgent decontamination, especially when every minute counts after toxin ingestion. But ropinirole offers practical advantages: it is FDA-approved, administered ophthalmically rather than by injection, and may be easier to use in some workflows. The 2025 emergency-room study also reflects how carefully selected these cases are in practice, with investigators excluding dogs in which emesis would be unsafe or less appropriate. Available guidance underscores that emesis should be avoided in cases such as corrosive or hydrocarbon ingestion, neurologic depression, shock, or respiratory compromise. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect more discussion around case selection, adverse-event management, and whether future emergency-room data shifts practice toward apomorphine for rapid decontamination while reserving ropinirole for situations where labeled, injection-free administration is a priority. The newer trial’s referral-hospital design and randomized head-to-head approach are likely to make it a key reference point in those protocol conversations. (pubmed.ncbi.nlm.nih.gov)